Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant commercial reward for some well-entrenched current therapies. Emerging agents such as AbbVie/Roche/Genentech’s Venclexta/Venclyxto, Karyopharm Therapeutics’ selinexor, Sanofi/ImmunoGen’s isatuximab, and Bluebird Bio/Celgene’s bb2121 are pursuing initial approvals for the treatment of multiple myeloma, highlighting that untapped clinical and commercial potential exists in multiple myeloma for therapies with improved efficacy, novel mechanisms of action, and positioned in patient segments that are currently underserved.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Already a Client? Log in to access this report.
Since October 2015, Dr. Wilcock has been a Business Insights Analyst in the oncology team at Decision Resources Group. He has experience in various indications including metastatic malignant melanoma and renal cell carcinoma, and will have a major focus on gastric cancer going forward. Previously, Dr. Wilcock was a Research Funding Manager at Cancer Research UK, where he developed a deep understanding of drug discovery, predominantly in the academic setting. He gained his doctorate from the University of Manchester where he utilized Systems Biology to explore the role of cell signaling and hypoxia in oral cancer.
Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.